Robert E Widdop

List of Publications by Year
in descending order

114 papers	5,541 citations	57758 44 h-index	85541 71 g-index
133 all docs	133 docs citations	133 times ranked	5249 citing authors

#	Article	IF	Citations
1	Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends in Pharmacological Sciences, 2008, 29, 601-608.	8.7	243
2	Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clinical Science, 2011, 121, 297-303.	4.3	241
3	Angiotensin AT2receptors: cardiovascular hope or hype?. British Journal of Pharmacology, 2003, 140, 809-824.	5.4	201
4	Angiotensin-(1â€“7) Acts as a Vasodepressor Agent Via Angiotensin II Type 2 Receptors in Conscious Rats. Hypertension, 2005, 45, 960-966.	2.7	183
5	Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3750-3755.	7.1	180
6	A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE^{-/-} mouse model. Diabetes and Vascular Disease Research, 2011, 8, 117-124.	2.0	152
7	AT ₂ Receptor-Mediated Relaxation Is Preserved After Long-Term AT ₁ Receptor Blockade. Hypertension, 2002, 40, 516-520.	2.7	146
8	Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein Eâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1606-1613.	2.4	145
9	Enhanced Angiotensin II Type 2 Receptor Mechanisms Mediate Decreases in Arterial Pressure Attributable to Chronic Low-Dose Angiotensin II in Female Rats. Hypertension, 2008, 52, 666-671.	2.7	143
10	AT ₂ Receptor Stimulation Enhances Antihypertensive Effect of AT ₁ Receptor Antagonist in Hypertensive Rats. Hypertension, 1999, 34, 1112-1116.	2.7	137
11	The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE^{â^'/â^'} mouse model. Diabetes and Vascular Disease Research, 2013, 10, 353-360.	2.0	121
12	Restraint Stress. Hypertension, 2000, 35, 126-129.	2.7	113
13	Gender Differences in Pressure-Natriuresis and Renal Autoregulation. Hypertension, 2011, 57, 275-282.	2.7	112
14	Reversal of Vascular Macrophage Accumulation and Hypertension by a CCR2 Antagonist in Deoxycorticosterone/Salt-Treated Mice. Hypertension, 2012, 60, 1207-1212.	2.7	103
15	Nitroxyl Anion Donor, Angeliâ€™s Salt, Does Not Develop Tolerance in Rat Isolated Aortae. Hypertension, 2007, 49, 885-892.	2.7	102
16	Angiotensin AT ₂ Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke. Stroke, 2009, 40, 1482-1489.	2.0	101
17	High Blood Pressure Reduction Reverses Angiotensin II Type 2 Receptorâ€“Mediated Vasoconstriction Into Vasodilation in Spontaneously Hypertensive Rats. Circulation, 2005, 111, 1006-1011.	1.6	98
18	Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney International, 2014, 86, 75-85.	5.2	98

#	Article	IF	Citations
19	Non-peptide AT2-receptor agonists. Current Opinion in Pharmacology, 2011, 11, 187-192.	3.5	96
20	Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. Hypertension, 2012, 59, 409-414.	2.7	95
21	Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease. Hypertension, 2014, 64, 315-322.	2.7	86
22	Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. Hypertension, 2012, 59, 129-135.	2.7	84
23	Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diabetes and Vascular Disease Research, 2018, 15, 64-73.	2.0	82
24	Angiotensin AT receptor contributes to cardiovascular remodelling of aged rats during chronic AT receptor blockade. Journal of Molecular and Cellular Cardiology, 2004, 37, 1023-1030.	1.9	81
25	Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. British Journal of Pharmacology, 2003, 140, 987-995.	5.4	80
26	Protective arms of the reninâ€“angiotensinâ€system in neurological disease. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 580-588.	1.9	75
27	AT₂ receptorâ€mediated vasodilatation is unmasked by AT₁ receptor blockade in conscious SHR. British Journal of Pharmacology, 2004, 142, 821-830.	5.4	72
28	Direct Angiotensin AT2 Receptor Stimulation Using a Novel AT2 Receptor Agonist, Compound 21, Evokes Neuroprotection in Conscious Hypertensive Rats. PLoS ONE, 2014, 9, e95762.	2.5	72
29	Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovascular Research, 2008, 77, 178-187.	3.8	71
30	Medial prefrontal cortical integration of psychological stress in rats. European Journal of Neuroscience, 2004, 20, 2430-2440.	2.6	60
31	Anti-fibrotic Potential of AT2 Receptor Agonists. Frontiers in Pharmacology, 2017, 8, 564.	3.5	58
32	Immunolocalization of ACE2 and AT2 Receptors in Rabbit Atherosclerotic Plaques. Journal of Histochemistry and Cytochemistry, 2006, 54, 147-150.	2.5	57
33	Sex- and age-related differences in the chronic pressure-natriuresis relationship: role of the angiotensin type 2 receptor. American Journal of Physiology - Renal Physiology, 2014, 307, F901-F907.	2.7	55
34	PcTx1 affords neuroprotection in a conscious model of stroke in hypertensive rats via selective inhibition of ASIC1a. Neuropharmacology, 2015, 99, 650-657.	4.1	55
35	Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. Hypertension, 2012, 60, 1531-1537.	2.7	54
36	Differential cardiovascular responses to stressors in hypertensive and normotensive rats. Experimental Physiology, 2005, 90, 141-150.	2.0	53

#	Article	IF	Citations
37	EARLY ORIGINS OF CARDIAC HYPERTROPHY: DOES CARDIOMYOCYTE ATTRITION PROGRAMME FOR PATHOLOGICAL â€˜CATCHâ€UPâ€™ GROWTH OF THE HEART?. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1358-1364.	1.9	53
38	Cardiovascular Effects of Angiotensin-(1â€“7) in Conscious Spontaneously Hypertensive Rats. Hypertension, 1999, 34, 964-968.	2.7	52
39	A Novel Histone Deacetylase Inhibitor Reduces Abdominal Aortic Aneurysm Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice. Journal of Vascular Research, 2008, 45, 143-152.	1.4	51
40	A Single Î²-Amino Acid Substitution to Angiotensin II Confers AT ₂ Receptor Selectivity and Vascular Function. Hypertension, 2011, 57, 570-576.	2.7	51
41	Update on the Angiotensin AT2 Receptor. Current Hypertension Reports, 2013, 15, 25-30.	3.5	51
42	Compound 21, a selective agonist of angiotensin AT₂ receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. British Journal of Pharmacology, 2016, 173, 729-740.	5.4	51
43	Angiotensin Type 2 Receptor Stimulation Increases Renal Function in Female, but Not Male, Spontaneously Hypertensive Rats. Hypertension, 2014, 64, 378-383.	2.7	49
44	High Methionine and Cholesterol Diet Abolishes Endothelial Relaxation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1358-1363.	2.4	48
45	Central autonomic integration of psychological stressors: Focus on cardiovascular modulation. Autonomic Neuroscience: Basic and Clinical, 2005, 123, 1-11.	2.8	45
46	Modulation of AT₁ receptorâ€mediated contraction of rat uterine artery by AT₂ receptors. British Journal of Pharmacology, 1998, 125, 1429-1436.	5.4	43
47	A Simple Versatile Method for Measuring Tail Cuff Systolic Blood Pressure in Conscious Rats. Clinical Science, 1997, 93, 191-194.	4.3	42
48	Disparate Roles of AT 2 Receptors in the Renal Cortical and Medullary Circulations of Anesthetized Rabbits. Hypertension, 2003, 42, 200-205.	2.7	42
49	Differential Phenotypes of Tissue-Infiltrating T Cells during Angiotensin II-Induced Hypertension in Mice. PLoS ONE, 2014, 9, e114895.	2.5	40
50	Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. Journal of Molecular Medicine, 2016, 94, 957-966.	3.9	39
51	Non-invasive tests of neurovascular function: Reduced responses in diabetes mellitus. Neuroscience Letters, 1987, 81, 177-182.	2.1	36
52	VASCULAR ANGIOTENSIN AT2RECEPTORS IN HYPERTENSION AND AGEING. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 386-390.	1.9	35
53	Chronic Administration of the HNO Donor Angeli's Salt Does Not Lead to Tolerance, Cross-Tolerance, or Endothelial Dysfunction: Comparison with GTN and DEA/NO. Antioxidants and Redox Signaling, 2011, 14, 1615-1624.	5.4	35
54	AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis. Journal of the American Society of Nephrology: JASN, 2019, 30, 2191-2207.	6.1	35

#	Article	IF	Citations
55	Î²-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats. Clinical Science, 2015, 129, 505-513.	4.3	34
56	Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diabetes and Vascular Disease Research, 2016, 13, 56-68.	2.0	34
57	Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia. Journal of the Autonomic Nervous System, 1994, 46, 65-73.	1.9	32
58	Brain and retinal microglia in health and disease: An unrecognized target of the reninâ€“angiotensin system. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 571-579.	1.9	32
59	Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II. ACS Chemical Biology, 2014, 9, 1420-1425.	3.4	31
60	Pressor responsiveness to angiotensin II in female mice is enhanced with age: role of the angiotensin type 2 receptor. Biology of Sex Differences, 2014, 5, 13.	4.1	30
61	Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Experimental & Translational Stroke Medicine, 2012, 4, 16.	3.2	29
62	Decorated self-assembling Î²³-tripeptide foldamers form cell adhesive scaffolds. Chemical Communications, 2016, 52, 4549-4552.	4.1	29
63	Intrathecal kynurenate reduces arterial pressure, heart rate and baroreceptor-heart rate reflex in conscious rats. Neuroscience Letters, 1990, 114, 309-315.	2.1	26
64	Effect of a Selective Mas Receptor Agonist in Cerebral Ischemia In Vitro and In Vivo. PLoS ONE, 2015, 10, e0142087.	2.5	26
65	AT2 receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. British Journal of Pharmacology, 2005, 144, 486-492.	5.4	25
66	Direct AT2 receptor stimulation is athero-protective and stabilizes plaque in Apolipoprotein E-deficient mice. International Journal of Cardiology, 2013, 169, 281-287.	1.7	25
67	Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. Atherosclerosis, 2008, 200, 37-44.	0.8	24
68	Characterisation of vasopressin V1A, angiotensin AT1 and AT2 receptor distribution and density in normotensive and hypertensive rat brain stem and kidney: effects of restraint stress11Published on the World Wide Web on 2 October 2000.. Brain Research, 2000, 883, 148-156.	2.2	22
69	Role of Inflammation and the Angiotensin Type 2 Receptor in the Regulation of Arterial Pressure During Pregnancy in Mice. Hypertension, 2014, 64, 626-631.	2.7	20
70	Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats. Brain Research, 1994, 648, 46-52.	2.2	19
71	SEXâ€DIFFERENCES IN CIRCADIAN BLOOD PRESSURE VARIATIONS IN RESPONSE TO CHRONIC ANGIOTENSIN II INFUSION IN RATS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 391-395.	1.9	19
72	The antiâ€fibrotic actions of relaxin are mediated through AT₂Râ€associated protein phosphatases via RXFP1â€AT₂R functional crosstalk in human cardiac myofibroblasts. FASEB Journal, 2020, 34, 8217-8233.	0.5	18

#	Article	IF	Citations
73	Differential gene expression in WKY and SHR brain following acute and chronic air-puff stress. Molecular Brain Research, 2005, 133, 329-336.	2.3	17
74	Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2. Frontiers in Pharmacology, 2015, 6, 5.	3.5	17
75	Regional Hemodynamic Effects of the AT 1 Receptor Antagonist CV-11974 in Conscious Renal Hypertensive Rats. Hypertension, 1995, 26, 989-997.	2.7	17
76	Angiotensin Type I Receptor Antagonists CY-11974 and EXP 3174 Cause Selective Renal Vasodilatation in Conscious Spontaneously Hypertensive Rats. Clinical Science, 1996, 91, 147-154.	4.3	16
77	A comparison of the development of renal hypertension in male and female rats. Clinical Science, 1998, 95, 445-451.	4.3	16
78	Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. Free Radical Biology and Medicine, 2020, 160, 391-402.	2.9	16
79	Serelaxin and the AT₂ Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil. ACS Pharmacology and Translational Science, 2020, 3, 76-87.	4.9	15
80	Renal functional effects of the highly selective AT2R agonist, Î²-Pro7 Ang III, in normotensive rats. Clinical Science, 2020, 134, 871-884.	4.3	15
81	Localization of AT2 receptors in the nucleus of the solitary tract of spontaneously hypertensive and Wistar Kyoto rats using [125I] CGP42112: upregulation of a non-angiotensin II binding site following unilateral nodose ganglionectomy. Brain Research, 2003, 968, 139-155.	2.2	14
82	Differential regulation by AT1 and AT2 receptors of angiotensin II-stimulated cyclic GMP production in rat uterine artery and aorta. British Journal of Pharmacology, 2004, 141, 1024-1031.	5.4	14
83	Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R872-R879.	1.8	13
84	Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. Current Hypertension Reports, 2004, 6, 117-123.	3.5	12
85	The effect of tocopheryl phosphates (TPM) on the development of atherosclerosis in apolipoproteinâ€E deficient mice. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 107-116.	1.9	12
86	Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/saltâ€induced hypertension. British Journal of Pharmacology, 2021, 178, 1164-1181.	5.4	12
87	Preclinical rodent models of cardiac fibrosis. British Journal of Pharmacology, 2022, 179, 882-899.	5.4	12
88	Esterase-Mediated Sustained Release of Peptide-Based Therapeutics from a Self-Assembled Injectable Hydrogel. ACS Applied Materials & Interfaces, 2021, 13, 58279-58290.	8.0	11
89	Postjunctional Î±₂â€adrenoceptors mediate venoconstriction in the hindquarters circulation of anaesthetized cats. British Journal of Pharmacology, 1987, 92, 121-128.	5.4	10
90	Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats. British Journal of Pharmacology, 1999, 128, 823-829.	5.4	10

#	Article	IF	Citations
91	In Aged Females, the Enhanced Pressor Response to Angiotensin II Is Attenuated By Estrogen Replacement via an Angiotensin Type 2 Receptor-Mediated Mechanism. Hypertension, 2021, 78, 128-137.	2.7	9
92	Ganging up on Angiotensin II Type 1 Receptors in Vascular Remodeling. Hypertension, 2012, 60, 17-19.	2.7	8
93	A Series of Analogues to the AT₂R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode. ChemistryOpen, 2019, 8, 114-125.	1.9	8
94	Assessment of renal fibrosis and antiâ€fibrotic agents using a novel diagnostic and stainâ€free secondâ€harmonic generation platform. FASEB Journal, 2021, 35, e21595.	0.5	8
95	Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice. Biomedicine and Pharmacotherapy, 2021, 144, 112256.	5.6	8
96	Electrophysiological studies of the cholecystokininA receptor antagonists SR27897B and PD140548 in the rat isolated nodose ganglion. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 353, 693-697.	3.0	7
97	Morphology and Function of the Lamb Ileum following Preterm Birth. Frontiers in Pediatrics, 2018, 6, 8.	1.9	7
98	Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity. Chemistry - A European Journal, 2020, 26, 10690-10694.	3.3	7
99	Relaxin Attenuates Organ Fibrosis via an Angiotensin Type 2 Receptor Mechanism in Aged Hypertensive Female Rats. Kidney360, 2021, 2, 1781-1792.	2.1	7
100	Optimising the photothrombotic model of stroke in the C57Bl/6 and FVB/N strains of mouse. Scientific Reports, 2022, 12, 7598.	3.3	7
101	ROLE OF THE BRAIN RENIN-ANGIOTENSIN SYSTEM IN THE MAINTENANCE OF BLOOD PRESSURE IN CONSCIOUS SPONTANEOUSLY HYPERTENSIVE AND SINOAORTIC BARORECEPTOR-DENERVATED RATS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 667-672.	1.9	6
102	Pharmacodynamic Contribution to the Vasodilator Effect of Chronic AT 1 Receptor Blockade in SHR. Hypertension, 2001, 37, 91-98.	2.7	6
103	N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands. Bioorganic and Medicinal Chemistry, 2021, 29, 115859.	3.0	6
104	Î²â€amino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2). Journal of Molecular Recognition, 2011, 24, 235-244.	2.1	5
105	Novel approaches for treating hypertension. F1000Research, 2017, 6, 80.	1.6	5
106	Functional Cardiovascular Effects of Angiotensin Peptides: Focus on Atherosclerosis and Hypertension. Current Hypertension Reviews, 2009, 5, 227-236.	0.9	4
107	A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia. Cardiovascular Drugs and Therapy, 2019, 33, 687-692.	2.6	3
108	Response to Letter by Tsuda. Stroke, 2009, 40, .	2.0	1

#	Article	IF	Citations
109	The effects of B-HT 920 and St 91 on venous haemodynamics in cats. Journal of Pharmacy and Pharmacology, 2011, 41, 55-56.	2.4	1
110	Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT2R selectivity and proteolytic stability. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128086.	2.2	1
111	Response to Can the Study of Female Rats Help Our Understanding of Women?. Hypertension, 2008, 52, .	2.7	0
112	Antiâ€atherosclerotic effects of the hexapeptide angiotensin IV. FASEB Journal, 2008, 22, 639-639.	0.5	0
113	Differential roles for tissueâ€infiltrating T cells during angiotensin IIâ€induced hypertension. FASEB Journal, 2013, 27, 708.6.	0.5	0
114	CCL18 as a potential mediator of the pro-fibrotic actions of M2 macrophages in the vessel wall during hypertension. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR1-4.	0.0	0